Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
Authors Kano O, Urita Y, Ito H, Takazawa T, Kawase Y, Murata K, Hirayama T, Miura K, Ishikawa Y, Kiyozuka T, Aoyagi J, Iwasaki Y
Received 18 June 2013
Accepted for publication 19 August 2013
Published 18 September 2013 Volume 2013:9 Pages 1411—1415
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 5
Osamu Kano,1 Yoshihisa Urita,2 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Takehisa Hirayama,1 Ken Miura,1 Yuichi Ishikawa,1 Tetsuhito Kiyozuka,3 Jo Aoyagi,3 Yasuo Iwasaki1
1Department of Neurology, 2Department of General Medicine and Emergency Care, Toho University Omori Medical Center, Tokyo, Japan; 3Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations, Mishuku Hospital, Tokyo, Japan
Objective: While acetylcholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, are beneficial in treating behavioral symptoms of patients with Alzheimer's disease (AD), their dose-limiting effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. We aimed to predict the occurrence of these gastrointestinal disturbances with rivastigmine therapy for optimal drug choice and improved compliance.
Materials and methods: Thirty patients with mild-to-moderate AD (scores 10–22 on the Mini-Mental State Examination) were administered a rivastigmine 18 mg patch with domperidone 30 mg (RWD) and without domperidone (RWOD; n = 15 each) for 20 weeks. Gastrointestinal disturbances were evaluated using a frequency scale for symptoms of gastroesophageal reflux disease (FSSG), Bristol stool form scale, laboratory data (hemoglobin, albumin, total cholesterol), body weight, and amount of food intake.
Results: After 12 weeks, FSSG scores were higher in the RWOD group compared to baseline scores; however, no significant differences were noted between the RWD and RWOD groups. We then subdivided each group based on high and low baseline scores; the RWOD high-score (≥4) subgroup showed increased FSSG after 12 weeks compared with the baseline score. In both RWD and RWOD groups, the low-score (≤3) subgroups showed no changes during the dose-escalation phase.
Conclusion: For AD patients with higher FSSG scores at baseline, domperidone was effective in preventing rivastigmine-related gastrointestinal disturbances.
Keywords: Alzheimer's disease, acetylcholinesterase inhibitors, domperidone, gastroesophageal reflux disease, gastrointestinal disturbance, rivastigmine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]